Estrogen and progesterone receptors (ER and PR) are widely expressed in normal and tumor ovarian tissues [2,3] For this reason, tamoxifen and aromatase inhibitors have been utilized in patients with recurrent ovarian cancer who have progressed after platinum-based chemotherapy [4]. Here, PGR is linked to ovarian cancer.